Nexalin Technology Inc. (NXL)
NASDAQ: NXL
· Real-Time Price · USD
0.79
-0.05 (-5.73%)
At close: Aug 14, 2025, 3:59 PM
0.79
-0.11%
After-hours: Aug 14, 2025, 07:32 PM EDT
-5.73% (1D)
| Bid | 0.75 |
| Market Cap | 13.76M |
| Revenue (ttm) | 131.06K |
| Net Income (ttm) | -8.55M |
| EPS (ttm) | -0.77 |
| PE Ratio (ttm) | -1.03 |
| Forward PE | -1.7 |
| Analyst | Buy |
| Ask | 0.96 |
| Volume | 95,585 |
| Avg. Volume (20D) | 95,838 |
| Open | 0.84 |
| Previous Close | 0.84 |
| Day's Range | 0.78 - 0.87 |
| 52-Week Range | 0.59 - 4.49 |
| Beta | 3.73 |
Analyst Forecast
According to 0 analyst ratings, the average rating for NXL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Nexalin Technology has released their quartely earnings
on Aug 6, 2025:
Next Earnings Release
Nexalin Technology Inc. is scheduled to release its earnings on
Nov 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-25.7%
Nexalin Technology shares are trading lower after ...
Unlock content with
Pro Subscription
9 months ago
+26.91%
Nexalin Technology shares are trading higher after the company announced it regained listing requirements compliance with Nasdaq.
1 year ago · proactiveinvestors.com
Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veteransNexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury...
